Epitopea is building a pipeline of first-in-class mRNA cancer immunotherapies that combine multiple, shared Cryptigens™ into a single, off-the-shelf modality capable of activating targeted, durable anti-tumor immunity.
Our lead program, CryptiVax™-1001, is advancing into clinical development for high-grade serous ovarian cancer (HGSOC). This immunotherapy incorporates validated, tumor-presented Cryptigens™ that are presented by the most prevalent HLA allotypes, thereby allowing coverage of the majority of HGSOC patients.
Beyond ovarian cancer, we are expanding our pipeline into other indications, each leveraging newly discovered Cryptigen™ repertoires.
